MIR-146A AN IMPORTANT KEY PLAYER IN BONE

OBJECTIVES

Our aim is to analyse the function of miR-146a in bone remodelling, its influence on bone stability and development of osteoporosis is not known.

METHODS

Systemic bone, tibiae and femur, of wt and miR-146a deficient animals was assessed histologically and via μCT analysis, over a period of 3 to 18 months of age. Serum cytokine levels were analysed by Elisa. MRNA expression levels in bone were analysed by qPCR. To induce osteoporosis, ovariotomy (OVX) induced bone loss was performed.

RESULTS

When we analysed bone volume of long bones histologically as well as with μCT analysis we detected significantly increased trabecular bone mass in miR-146a deficient compared to wt animals, starting at an age of 6 months. In addition cortical thickness of systemic bones from miR-146a knock out animals was significantly increased compared to control mice. Analysis of serum in aged miR-146a deficient animals displayed elevated activity of bone resoring osteoclasts as amounts of CTX I in miR-146a−/− mice were significantly increased compared to wt animals. Q-PCR analysis of important osteoclast as well as osteoblast marker genes in bones ex vivo displayed elevated expression of signature molecules of both cell types in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both osteoclasts as well as osteoblasts. When we induced osteoporosis using the OVX disease model, histological analysis of long bones showed significant trabecular bone loss in ovariotomized wt mice. In contrast, we detected no trabecular bone loss in ovariotomized miR-146a knock out animals, suggesting that loss of miR-146a deficiency protects bone loss induced by estrogen deficiency.

CONCLUSIONS

MiR-146a seems to control bone turnover and miR-146a deficient mice accrue bone over time. Moreover this miRNA has a negative influence on bone loss occurring during oestrogen loss induced osteoporosis. Therefore miR-146a could be possibly used as a therapeutic target in the treatment of osteoporosis.

Disclosure of Interest None declared.